4.6 Review

Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook

期刊

EPMA JOURNAL
卷 14, 期 1, 页码 143-165

出版社

SPRINGER INT PUBL AG
DOI: 10.1007/s13167-023-00312-w

关键词

Microsatellite instability; Cancer; Screening; Massively parallel sequencing; Liquid biopsy; Patient stratification; Predictive Preventive Personalised Medicine (PPPM; 3PM)

向作者/读者索取更多资源

Microsatellite instability (MSI) is a form of genomic alteration caused by the failure of a post-replicative DNA mismatch repair (MMR) system in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs). Traditional strategies for determining MSI events are low-throughput procedures that require assessment of both tumor and healthy samples. However, recent large-scale pan-tumor studies have shown the potential of massively parallel sequencing (MPS) in detecting MSI.
A form of genomic alteration called microsatellite instability (MSI) occurs in a class of tandem repeats (TRs) called microsatellites (MSs) or short tandem repeats (STRs) due to the failure of a post-replicative DNA mismatch repair (MMR) system. Traditionally, the strategies for determining MSI events have been low-throughput procedures that typically require assessment of tumours as well as healthy samples. On the other hand, recent large-scale pan-tumour studies have consistently highlighted the potential of massively parallel sequencing (MPS) on the MSI scale. As a result of recent innovations, minimally invasive methods show a high potential to be integrated into the clinical routine and delivery of adapted medical care to all patients. Along with advances in sequencing technologies and their ever-increasing cost-effectiveness, they may bring about a new era of Predictive, Preventive and Personalised Medicine (3PM). In this paper, we offered a comprehensive analysis of high-throughput strategies and computational tools for the calling and assessment of MSI events, including whole-genome, whole-exome and targeted sequencing approaches. We also discussed in detail the detection of MSI status by current MPS blood-based methods and we hypothesised how they may contribute to the shift from conventional medicine to predictive diagnosis, targeted prevention and personalised medical services. Increasing the efficacy of patient stratification based on MSI status is crucial for tailored decision-making. Contextually, this paper highlights drawbacks both at the technical level and those embedded deeper in cellular/molecular processes and future applications in routine clinical testing.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据